Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: Data from the AWARD-1 and AWARD-3 clinical trials

Diabetes, Obesity and Metabolism

Volumn 17, Issue 9, 2015, Pages 896-903

  Reaney, M ^a   Yu, M ^b   Lakshmanan, M ^b   Pechtner, V ^b   Van Brunt, K ^b  

^a ERT   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Type 2 diabetes

Indexed keywords

DULAGLUTIDE; EXENDIN 4; METFORMIN; PLACEBO; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; PEPTIDE; VENOM;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT PLANNING; VOMITING; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; DIABETES MELLITUS; DRUG ADMINISTRATION; MIDDLE AGED; PSYCHOLOGY; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA; TIME FACTOR;

ADULT; DIABETES MELLITUS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCAGON-LIKE PEPTIDES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; MALE; METFORMIN; MIDDLE AGED; PATIENT SATISFACTION; PEPTIDES; RECOMBINANT FUSION PROTEINS; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; VENOMS;

EID: 84939478562     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12527     Document Type: Article

References (30)

1. International Diabetes Federation. IDF Diabetes Atlas. 6th edn. Brussels: International Diabetes Federation, 2013.
2. Inzucchi SE, Bergenstal RM, Buse JB etal. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
3. Wysham C, Blevins T, Arakaki R etal. Efficacy and safety of dulaglutide added on to pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care 2014; 37: 2159-2167.
4. Umpierrez G, Tofé Povedano S, Pérez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care 2014; 37: 2168-2176.
5. Nauck MA, Weinstock RS, Umpierrez GE etal. Efficacy and safety of dulaglutide vs. sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014; 37: 2149-2158.
6. Giorgino F, Benroubi M, Sun J, Zimmermann A, Pechtner V. Efficacy and safety of once weekly dulaglutide versus insulin glargine in combination with metformin and glimepiride in type 2 diabetes (AWARD-2). American Diabetes Association - 74th Annual Scientific Sessions. Diabetes 2014; 63(Suppl. 1): A87.
7. World Health Organization. Preamble to the Constitution of the World Health Organization as Adopted by the International Health Conference, New York, 19-22 June 1946. Geneva: World Health Organization, 1948.
8. Barbosa CD, Balp MM, Kulich K, Germain N, Rofail D. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adherence 2012; 6: 39-48.
9. Davies M, Speight J. Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2012; 14: 882-892.
10. Bradley C, Gamzu DS. Guidelines for encouraging psychological well-being: report of a Working Group of the World Health Organization Regional Office for Europe and International Diabetes Federation European Region St Vincent Declaration Action Programme for Diabetes. Diabet Med 1994; 11: 510-516.
11. Hermansen K, Kolotkin RL, Hammer M, Zdravkovic M, Matthews D. Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin. Prim Care Diabetes 2010; 4: 113-117.
12. Davies M, Pratley R, Hammer M, Thomsen AB, Cuddihy R. Liraglutide improves treatment satisfaction in people with type 2 diabetes compared with sitagliptin, each as an add on to metformin. Diabet Med 2011; 28: 333-337.
13. Pratley RE, Nauck MA, Bailey T etal. One year of Liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 2011; 65: 397-407.
14. Lind M, Jendle J, Torffvit O, Lager I. Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Prim Care Diabetes 2012; 6: 41-46.
15. Bradley C. The Diabetes Treatment Satisfaction Questionnaire (DTSQ). In: Bradley C, ed. Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice. Chur: Harwood Academic Publishers, 1994 p. 111-132.
16. Bradley C. Diabetes treatment satisfaction questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur. Diabetes Care 1999; 22: 530-532.
17. Hayes RP, Nelson DR, Meldahl ML, Curtis BH. Ability to perform daily physical activities in individuals with type 2 diabetes and moderate obesity: a preliminary validation of the Impact of Weight on Activities of Daily Living Questionnaire. Diabetes Technol Ther 2011; 13: 705-712.
18. Hayes RP, Schultz EM, Naegeli AN, Curtis BH. Test-retest, responsiveness, and minimal important change of the ability to perform physical activities of daily living questionnaire in individuals with type 2 diabetes and obesity. Diabetes Technol Ther 2012; 14: 1118-1125.
19. Polonsky WH, Fisher L, Hessler D, Bruhn D, Best JH. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab 2011; 13: 144-149.
20. Kinmonth AL, Woodcock A, Griffin S, Spiegal N, Campbell MJ. Randomised controlled trial of patient centred care of diabetes in general practice: impact on current wellbeing and future disease risk. BMJ 1998; 317: 1202-1208.
21. Bradley C, Speight J. Patient perceptions of diabetes and diabetes therapy: assessing quality of life. Diabetes Metab Res Rev 2002; 18(Suppl. 3): S64-69.
22. Albrecht G, Hoogstraten J. Satisfaction as determinant of compliance. Community Dent Oral Epidemiol 1998; 26: 139-146.
23. Menzin J, Langley-Hawthorne C, Friedman M, Boulanger L, Cavanaugh R. Potential short-term economic benefits of improved glycemic control: a managed care perspective. Diabetes Care 2001; 24: 51-55.
24. Hogan P, Dall T, Nikolov P, American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care 2003; 26: 917-932.
25. Nicolucci A, Cucinotta D, Squatrito S etal. Clinical and socio-economic correlates of quality of life and treatment satisfaction in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis 2009; 19: 45-53.
26. Pala T, Eser E, Ozmen B, Aydemir O, Boyvoda S. The determinants of quality of life including treatment satisfaction in patients with type two diabetes mellitus: are different generic Qol instruments sensitive to the same determinants? Turkish J Endocrinol Metab 2004; 3: 91-99.
27. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care 2010; 33: 240-245.
28. Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med 2008; 31: 213-224.
29. Renard E, Apostol D, Lauton D, Boulet F, Bringer J. Quality of life in diabetic patients treated by insulin pumps. Qual Life Newsl 2002; 28: 11-13. Available from URL: http://www.pro-newsletter.com/images/PDF/qol28.pdf. Accessed 6 July 2015.
30. Best JH, Boye KS, Rubin RR, Cao D, Kim TH, Peyrot M. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet Med 2009; 26: 722-728.